Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher · 2026
Read Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review by Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13341420.txt.
Description
Henry D. Heisey and colleagues reviewed GLP-1 drug stopping and adherence in 2026 through a narrative review framed by an established adherence model for chronic disease. GLP-1 drugs are increasingly used for glucose lowering and weight management, yet many patients stop them. Definitions of stopping, adherence, and persistence vary widely across studies, hampering comparison.
Few qualitative studies focus on why patients stop GLP-1 drugs, while quantitative work often stresses drug factors and superficial socioeconomic and condition factors. Very few studies cover all five dimensions of the adherence framework. The review maps gaps and urges richer, framework based research on why patients stay on or leave these widely used drugs.
Catalog record
| CREATOR | Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |